耐多药结核病的病灶异质性与长期异质性耐药
研究对31例耐多药结核病患者的83株连续分离株进行全基因组测序,在21例患者(67.74%)中检出异质性耐药。异质性耐药在宿主体内持续数月到数年,且与多发性结核病灶相关,可能影响治疗方案的成功。
要点
- 耐多药结核病患者中异质性耐药常见,检出率达67.74%。
- 异质性耐药可在宿主体内长期持续,跨越数月至数年。
- 多发性结核病灶与异质性耐药持续相关,可能影响治疗成效。
核心结论
- 异质性耐药在耐多药结核病患者中常见且持续存在,可能影响治疗方案的成功。
研究设计与样本
- 对31例耐多药结核病患者的83株连续分离株进行全基因组测序。
主要发现
- 在21例患者(67.74%)的分离株中检出异质性耐药。
- 异质性耐药在宿主体内持续数月到数年。
- 异质性耐药与患者具有多个结核病灶相关。
临床怎么用
- 对耐多药结核病患者应考虑异质性耐药可能,尤其存在多发病灶时。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tuberculosis heteroresistance, in which only a fraction of the bacteria in a patient with tuberculosis contains drug-resistant mutations, has been a rising concern. However, its origins and prevalence remain elusive. Here, whole-genome sequencing was performed on 83 serial isolates from 31 patients with multidrug-resistant tuberculosis, and heteroresistance was detected in isolates from 21 patients (67.74%). Heteroresistance persisted in the host for long periods, spanning months to years, and was associated with having multiple tubercular lesions. Our findings indicate that heteroresistance is common and persistent in patients with multidrug-resistant tuberculosis and may affect the success of their treatment regimens.
引用
- Chen Y, Ji L, Liu Q, et al. Lesion Heterogeneity and Long-Term Heteroresistance in Multidrug-Resistant Tuberculosis. J Infect Dis. 2021. PMID: 34467983. doi:10.1093/infdis/jiab011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。